Is anti-tumor necrosis factor therapy associated with increased mortality in patients with severe sepsis caused by pneumonia?

Journal of Infectious Diseases

Volumn 189, Issue 9, 2004, Pages 1743-

  Harbarth, Stephan ^a   Garbino, Jorge ^a   Pittet, Didier ^a   Pugin, Jérome ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; LENERCEPT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

BACTERIAL PNEUMONIA; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; LETTER; LOBAR PNEUMONIA; MORTALITY; MULTIVARIATE ANALYSIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES; COHORT STUDIES; DOUBLE-BLIND METHOD; HUMANS; LACTAMS; MICE; PNEUMONIA, PNEUMOCOCCAL; RETROSPECTIVE STUDIES; SEPSIS; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2442444902     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/383131     Document Type: Letter

References (3)

1. Rijneveld AW, Florquin S, Hartung T, Speelman P, van der Poll T. Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia. J Infect Dis 2003; 188:282-5.
2. Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29:503-10.
3. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334:1697-702.